{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:38:16Z","timestamp":1791563896769,"version":"4.3.4"},"reference-count":106,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Neuropsiquiatr"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuromuscular diseases (NMD) include a broad group of medical conditions with both acquired and genetic causes. In recent years, important advances have been made in the treatment of genetically caused NMD, and most of these advances are due to the implementation of therapies aimed at gene regulation. Among these therapies, gene replacement, small interfering RNA (siRNA), and antisense antinucleotides are the most promising approaches. More importantly, some of these therapies have already gained regulatory approval or are in the final stages of approval. The review focuses on motor neuron diseases, neuropathies, and Duchenne muscular dystrophy, summarizing the most recent developments in gene-based therapies for these conditions.<\/jats:p>","DOI":"10.1055\/s-0043-1777755","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T23:35:22Z","timestamp":1707348922000},"page":"001-010","source":"Crossref","is-referenced-by-count":4,"title":["Gene-based therapies for neuromuscular disorders"],"prefix":"10.1055","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4991-6760","authenticated-orcid":false,"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina, Departamento de Neurologia, S\u00e3o Paulo SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-2419","authenticated-orcid":false,"suffix":"Jr.","given":"Marcondes Cavalcante","family":"Fran\u00e7a","sequence":"additional","affiliation":[{"name":"Universidade Estadual de Campinas, Faculdade de Ci\u00eancias M\u00e9dicas, Departamento de Neurologia, Campinas SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-2749","authenticated-orcid":false,"suffix":"Jr.","given":"Wilson","family":"Marques","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo, Faculdade de Medicina de Ribeir\u00e3o Preto, Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Ribeir\u00e3o Preto SP, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3233\/JND-221540","article-title":"Gene Therapy for Neuromuscular Diseases: Health Economic Challenges and Future Perspectives","volume":"9","author":"E Landfeldt","year":"2022","journal-title":"J Neuromuscul Dis"},{"issue":"18","key":"ref2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"J R Mendell","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"ref3","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"R S Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"ref4","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"G Baranello","year":"2021","journal-title":"N Engl J Med"},{"issue":"01","key":"ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"M D Benson","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"D Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1136\/practneurol-2017-001764","article-title":"Antisense oligonucleotides and other genetic therapies made simple","volume":"18","author":"A M Rossor","year":"2018","journal-title":"Pract Neurol"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/mus.26001","article-title":"Making sense of antisense oligonucleotides: A narrative review","volume":"57","author":"N Goyal","year":"2018","journal-title":"Muscle Nerve"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"J K Lam","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nrg2971","article-title":"State-of-the-art gene-based therapies: the road ahead","volume":"12","author":"M A Kay","year":"2011","journal-title":"Nat Rev Genet"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1056\/NEJMc1710379","article-title":"Amyotrophic Lateral Sclerosis","volume":"377","author":"R H Brown Jr","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","article-title":"Amyotrophic lateral sclerosis: translating genetic discoveries into therapies","volume":"24","author":"F Ak\u00e7imen","year":"2023","journal-title":"Nat Rev Genet"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S1474-4422(17)30401-5","article-title":"Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications","volume":"17","author":"R Chia","year":"2018","journal-title":"Lancet Neurol"},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"T M Miller","year":"2022","journal-title":"N Engl J Med"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2005056","article-title":"SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS","volume":"383","author":"C Mueller","year":"2020","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/362059a0","article-title":"Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis","volume":"362","author":"D R Rosen","year":"1993","journal-title":"Nature"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","article-title":"Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study","volume":"19","author":"M Benatar","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13311-022-01247-2","article-title":"Antisense Oligonucleotides for the Study and Treatment of ALS","volume":"19","author":"B D Boros","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"292.e15","DOI":"10.1016\/j.neurobiolaging.2018.04.020","article-title":"Intermediate-length CAG repeat in ATXN2 is associated with increased risk for amyotrophic lateral sclerosis in Brazilian patients","volume":"69","author":"H M Tavares de Andrade","year":"2018","journal-title":"Neurobiol Aging"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"L A Becker","year":"2017","journal-title":"Nature"},{"issue":"01","key":"ref24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"S Lefebvre","year":"1995","journal-title":"Cell"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"S J Kolb","year":"2011","journal-title":"Arch Neurol"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","article-title":"209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands","volume":"25","author":"R Finkel","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1212\/NXG.0000000000000505","article-title":"Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy","volume":"6","author":"R H Mendon\u00e7a","year":"2020","journal-title":"Neurol Genet"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"M Calucho","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3390\/ijms21093297","article-title":"New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?","volume":"21","author":"T H Chen","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy","volume":"86","author":"C A Chiriboga","year":"2016","journal-title":"Neurology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"R S Finkel","year":"2016","journal-title":"Lancet"},{"issue":"07","key":"ref32","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"E Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"ref33","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies","volume":"92","author":"B T Darras","year":"2019","journal-title":"Neurology"},{"issue":"07","key":"ref34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2352-4642(21)00100-0","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: final report of a phase 2, open-label, multicentre, dose-escalation study","volume":"5","author":"R S Finkel","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"issue":"04","key":"ref35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"T Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"02","key":"ref36","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JND-200533","article-title":"Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen","volume":"8","author":"R de Holanda Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"01","key":"ref37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JND-200551","article-title":"Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience","volume":"8","author":"R H Mendon\u00e7a","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"02","key":"ref38","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","article-title":"Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis","volume":"19","author":"M Gavriilaki","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"11","key":"ref39","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"D C De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"02","key":"ref40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"T O Crawford","year":"2023","journal-title":"Muscle Nerve"},{"issue":"15","key":"ref41","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)","volume":"61","author":"H Ratni","year":"2018","journal-title":"J Med Chem"},{"issue":"05","key":"ref42","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/nejmoa2102047","article-title":"Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls","volume":"385","author":"B T Darras","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref44","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S1474-4422(22)00339-8","article-title":"Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial","volume":"21","author":"R Masson","year":"2022","journal-title":"Lancet Neurol"},{"issue":"07","key":"ref45","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","article-title":"Risdiplam in types 2 and 3 spinal muscular atrophy: A randomized, placebo-controlled, dose-finding trial followed by 24 months of treatment","volume":"30","author":"E Mercuri","year":"2023","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"E Mercuri","year":"2022","journal-title":"Lancet Neurol"},{"issue":"05","key":"ref47","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"M Oskoui","year":"2023","journal-title":"J Neurol"},{"issue":"02","key":"ref48","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40120-023-00444-1","article-title":"Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study","volume":"12","author":"C A Chiriboga","year":"2023","journal-title":"Neurol Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2866","article-title":"Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis","volume":"\u2022\u2022\u2022","author":"C Pascual-Morena","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"07","key":"ref50","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"J R Mendell","year":"2021","journal-title":"JAMA Neurol"},{"issue":"10","key":"ref51","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"E Mercuri","year":"2021","journal-title":"Lancet Neurol"},{"issue":"04","key":"ref52","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"J W Day","year":"2021","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","article-title":"Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study","volume":"6","author":"C Weiss","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"101997","DOI":"10.1016\/j.eclinm.2023.101997","article-title":"Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in na\u00efve patients with spinal muscular atrophy and following switch from other therapies","volume":"59","author":"M Pane","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"03","key":"ref55","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/jpc.16340","article-title":"Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis","volume":"59","author":"D Yang","year":"2023","journal-title":"J Paediatr Child Health"},{"issue":"07","key":"ref56","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","year":"2022","journal-title":"Nat Med"},{"issue":"07","key":"ref57","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"K A Strauss","journal-title":"Nat Med"},{"issue":"08","key":"ref58","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.nmd.2023.06.005","article-title":"Onasemnogene abeparvovec preserves bulbar function in infants with presymptomatic spinal muscular atrophy: a post-hoc analysis of the SPR1NT trial","volume":"33","author":"R D Shell","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"03","key":"ref59","doi-asserted-by":"publisher","first-page":"e36197","DOI":"10.7759\/cureus.36197","article-title":"Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)","volume":"15","author":"T Ogbonmide","year":"2023","journal-title":"Cureus"},{"issue":"14","key":"ref60","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"J Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"A Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"09","key":"ref62","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/jcpt.13733","article-title":"Hemophagocytic lymphohistiocytosis following gene replacement therapy in a child with type 1 spinal muscular atrophy","volume":"47","author":"F Galletta","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"113493","DOI":"10.1016\/j.jpeds.2023.113493","article-title":"Necrotizing Enterocolitis following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series","volume":"260","author":"J Gaillard","year":"2023","journal-title":"J Pediatr"},{"issue":"03","key":"ref64","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3233\/JND-221560","article-title":"Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)","volume":"10","author":"R S Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","article-title":"Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy","volume":"14","author":"L Poli","year":"2023","journal-title":"Front Neurol"},{"issue":"11","key":"ref66","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1474-4422(23)00334-4","article-title":"Hereditary transthyretin amyloid neuropathies: advances in pathophysiology, biomarkers, and treatment","volume":"22","author":"D Adams","year":"2023","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref67","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis","volume":"93","author":"A Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"08","key":"ref68","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/ene.14285","article-title":"Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial","volume":"27","author":"T H Brannagan","year":"2020","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","article-title":"Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen","volume":"12","author":"T Coelho","year":"2023","journal-title":"Neurol Ther"},{"issue":"15","key":"ref70","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy","volume":"330","author":"T Coelho","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"D Adams","year":"2021","journal-title":"Lancet Neurol"},{"issue":"06","key":"ref72","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/ajt.17009","article-title":"Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation","volume":"22","author":"H H Schmidt","year":"2022","journal-title":"Am J Transplant"},{"issue":"17","key":"ref73","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","volume":"389","author":"M S Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"01","key":"ref74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"D Adams","year":"2023","journal-title":"Amyloid"},{"issue":"06","key":"ref75","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"Crispr-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"J D Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"ref76","doi-asserted-by":"publisher","first-page":"e2389","DOI":"10.1002\/brb3.2389","article-title":"Acute porphyrias - A neurological perspective","volume":"11","author":"L M Gerischer","year":"2021","journal-title":"Brain Behav"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"M M Zhang","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"24","key":"ref78","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria","volume":"382","author":"M Balwani","year":"2020","journal-title":"N Engl J Med"},{"issue":"06","key":"ref79","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"E P Hoffman","year":"1987","journal-title":"Cell"},{"issue":"01","key":"ref80","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis","volume":"15","author":"S Crisafulli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"02","key":"ref81","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1006\/geno.1993.1225","article-title":"Exon structure of the human dystrophin gene","volume":"16","author":"R G Roberts","year":"1993","journal-title":"Genomics"},{"issue":"09","key":"ref82","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3390\/biom13091319","article-title":"Advances in Dystrophinopathy Diagnosis and Therapy","volume":"13","author":"F A Saad","year":"2023","journal-title":"Biomolecules"},{"issue":"01","key":"ref83","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","article-title":"An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus","volume":"2","author":"A P Monaco","year":"1988","journal-title":"Genomics"},{"issue":"01","key":"ref84","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1055\/s-0043-1761466","article-title":"Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy","volume":"81","author":"A PQC Araujo","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"issue":"10","key":"ref85","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"D Duan","year":"2018","journal-title":"Mol Ther"},{"issue":"09","key":"ref86","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"J R Mendell","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1\/2a nonrandomized trial","volume":"\u2022\u2022\u2022","author":"J R Mendell","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"J R Mendell","journal-title":"Front Cell Dev Biol"},{"issue":"05","key":"ref89","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged \u22654 to <8\u2009Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"C M Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"ref90","volume-title":"One year data from ambulatory boys in a phase 1b, open-label study of fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD)","author":"R Butterfield","year":"2023"},{"key":"ref91","volume-title":"IGNITE DMD Phase I\/II Study of SGT-001 Microdystrophin Gene Therapy for DMD: 2-Year Outcomes Update","author":"R D Dreghici","year":"2022"},{"key":"ref92","volume-title":"3-Year Outcomes Update in the IGNITE DMD Phase 1\/2 Study of SGT-001 Microdystrophin Gene Therapy","author":"R D Dreghici","year":"2023"},{"issue":"24","key":"ref93","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne's Muscular Dystrophy","volume":"388","author":"C G B\u00f6nnemann","year":"2023","journal-title":"N Engl J Med"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"14038","DOI":"10.1038\/mtm.2014.38","article-title":"Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells","volume":"1","author":"A LH Arnett","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"03","key":"ref95","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"A Aartsma-Rus","year":"2009","journal-title":"Hum Mutat"},{"issue":"05","key":"ref96","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"J R Mendell","year":"2013","journal-title":"Ann Neurol"},{"issue":"24","key":"ref97","doi-asserted-by":"publisher","first-page":"e2146","DOI":"10.1212\/WNL.0000000000005680","article-title":"Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production","volume":"90","author":"J S Charleston","year":"2018","journal-title":"Neurology"},{"issue":"02","key":"ref98","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"J R Mendell","year":"2016","journal-title":"Ann Neurol"},{"issue":"04","key":"ref99","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3233\/JND-200548","article-title":"Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls","volume":"8","author":"J R Mendell","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"06","key":"ref100","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial","volume":"8","author":"C M McDonald","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"08","key":"ref101","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"S Anwar","year":"2020","journal-title":"Drugs Today (Barc)"},{"issue":"21","key":"ref102","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"D E Frank","year":"2020","journal-title":"Neurology"},{"issue":"01","key":"ref103","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"L Servais","year":"2022","journal-title":"Nucleic Acid Ther"},{"issue":"01","key":"ref104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-020-01106-1","article-title":"The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy","volume":"9","author":"D Scaglioni","year":"2021","journal-title":"Acta Neuropathol Commun"},{"issue":"08","key":"ref105","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial","volume":"77","author":"P R Clemens","year":"2020","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref106","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study","volume":"10","author":"P R Clemens","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"44","key":"ref107","doi-asserted-by":"publisher","first-page":"12508","DOI":"10.1073\/pnas.1605336113","article-title":"Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression","volume":"113","author":"B Roy","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"04","key":"ref108","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","article-title":"Ataluren treatment of patients with nonsense mutation dystrophinopathy","volume":"50","author":"K Bushby","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","article-title":"Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"C M McDonald","year":"2017","journal-title":"Lancet"},{"issue":"08","key":"ref110","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1007\/s00415-023-11687-1","article-title":"Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis","volume":"270","author":"E Mercuri","year":"2023","journal-title":"J Neurol"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0043-1777755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:42:40Z","timestamp":1730803360000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0043-1777755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":106,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2024,2,7]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["s00431777755"],"URL":"https:\/\/doi.org\/10.1055\/s-0043-1777755","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0004-282X","1678-4227"],"issn-type":[{"value":"0004-282X","type":"print"},{"value":"1678-4227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}